Skip to main content
    E

    Edgewise Therapeutics Inc (EWTX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $42.04
    -1.64 (-3.75%)

    Market Cap: $5.03B

    Last updated: Nov 17, 2026 at 4:20 PM ET

    Edgewise Therapeutics Inc (EWTX) Valuation Multiples

    Updated Nov 17, 2026. Multiples are computed from end-of-day prices, company filings and consensus analyst estimates.

    Edgewise Therapeutics (EWTX) trades at 2.8x book value. Its P/B of 2.8x is in line with its 5-year median. Its forward P/E is 63.1x.

    Current Multiples

    Its enterprise value is 4.0x its EBITDA.

    MultipleValue
    P/E (trailing)N/A
    Forward P/E63.1x
    Price to book2.8x
    EV/EBITDA4.0x
    PEGN/A
    FCF yield-4.4%
    As of Nov 17, 2026

    Historical Medians

    MultipleCurrent5-year median10-year median
    P/B2.8x2.8xN/A
    Medians of month-end values through Oct 2026: 60 months (5-year).

    Valuation History

    Over the 5 year ends shown, its P/B ranged from 1.6x in 2022 to 5.4x in 2024.

    Year endPriceP/SP/B
    2025$24.82N/A4.9x
    2024$26.70N/A5.4x
    2023$10.94314.7x2.2x
    2022$8.94N/A1.6x
    2021$15.28N/A2.7x
    Each year's multiples use the split-adjusted closing price of that year's last trading day over trailing per-share results as reported.

    Frequently Asked Questions About EWTX

    What is EWTX's forward P/E ratio?

    Edgewise Therapeutics has a forward P/E ratio of 63.1x.